<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461186</url>
  </required_header>
  <id_info>
    <org_study_id>BAKMAL1501</org_study_id>
    <nct_id>NCT02461186</nct_id>
  </id_info>
  <brief_title>Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar</brief_title>
  <official_title>An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Medical Research, Lower Myanmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emerging resistance to artemisinins and their partner drugs severely threatens the treatment
      of falciparum malaria in Myanmar with artemisinin combination therapies. To inform drug
      policy, it is crucial to evaluate alternative antimalarial treatments.

      The investigators here propose a randomized clinical trial comparing parasite clearance
      parameters and efficacy of 3 days arterolane-piperaquine with standard treatment with 3 days
      dihydroartemisinin (DHA)-piperaquine in adult patients with uncomplicated falciparum malaria
      in Myanmar stratified for the presence of &quot;K13&quot; mutation in the infecting parasite strains.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      - To assess the parasite clearance half-life of arterolane-piperaquine compared to
      DHA-piperaquine in patients with artemisinin resistant uncomplicated falciparum malaria,
      defined by presence of the &quot;K13&quot; mutations in the infecting parasite strain.

      Secondary Objectives :

        -  To assess the therapeutic efficacy of arterolane-piperaquine and DHA-piperaquine for the
           treatment of uncomplicated falciparum malaria or mixed infection (P.falciparum (PF) + a
           non-falciparum species) at Day 42, stratified by presence of artemisinin resistance in
           the infecting parasite strain.

        -  To assess the frequency of adverse events and serious adverse events of
           arterolane-piperaquine compared to DHA-piperaquine.

        -  To assess other efficacy parameters related to parasite clearance and parasite cure rate
           as well as the gametocyte carriage.

        -  To obtain pharmacokinetic (PK) and pharmacokinetic/pharmacodynamics (PK/PD) data on
           arterolane-piperaquine and DHA-piperaquine.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change of the study site due to the current political climate in Myanmar.
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral blood parasite half-life</measure>
    <time_frame>2 years</time_frame>
    <description>Peripheral blood parasite half-life of the linear portion of the natural logarithm parasite clearance curve in patients with parasitaemia at inclusion &gt;10,000 parasites/µL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>42 day PCR corrected adequate clinical and parasitological response (ACPR)</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uncomplicated Falciparum Malaria</condition>
  <condition>Artemisinin-resistant</condition>
  <arm_group>
    <arm_group_label>Arterolane maleate-piperaquine phosphate (Synriam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin-piperaquine phosphate (Duocotexin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arterolane maleate-piperaquine phosphate (Synriam)</intervention_name>
    <arm_group_label>Arterolane maleate-piperaquine phosphate (Synriam)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-piperaquine phosphate (Duocotexin)</intervention_name>
    <arm_group_label>Dihydroartemisinin-piperaquine phosphate (Duocotexin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥ 18 year old

          -  Symptomatic malaria infection, i.e. history of fever or presence of fever &gt;37.5°c
             (tympanic) within the last 24 hours.

          -  Microscopic confirmation of asexual stages of P.falciparum (may be mixed with
             non-falciparum species) with a parasitaemia &gt;10,000 parasites/µL

          -  Able to take oral medication

          -  Willingness and ability of patients to comply with the study protocol for the duration
             of the study

          -  Written informed consent given to participate in the trial

        Exclusion Criteria:

          -  Pregnancy or lactation (urine test for β HCG to be performed on any woman of child
             bearing age 18 to 45 year old)

          -  P.falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells
             (175,000/µL).

          -  Signs or symptoms indicative of severe malaria:

               -  Impaired consciousness

               -  Severe anaemia (Hct&lt;15%)

               -  Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria,
                  bleeding from venipuncture sites

               -  Respiratory distress

               -  Severe jaundice

          -  Have taken a full course DHA-piperaquine, artemether-lumefantrin or other antimalarial
             treatment in the previous 42 days

          -  Known hypersensitivity to artemisinins or to piperaquine - defined as history of
             erythroderma/other severe cutaneous reaction or angioedema

          -  History of splenectomy

          -  History of taking medicinal products that are known to prolong the QTc interval,
             including:

               -  Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,
                  procainamide, quinidine, hydroquinidine, sotalol).

               -  Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,
                  haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.

               -  Certain antimicrobial agents, including agents of the following classes:

                    -  macrolides (e.g. erythromycin, clarithromycin),

                    -  fluoroquinolones (e.g. moxifloxacin, sparfloxacin),

                    -  imidazole and triazole antifungal agent,

                    -  pentamidine and saquinavir.

               -  The non-sedating antihistamines terfenadine, astemizole, mizolastine.

               -  Other drugs: cisapride, droperidol, domperidone, bepridil, diphemanil, probucol,
                  levomethadyl, methadone, vinca alkaloids, arsenic trioxide.

          -  History of taking any drug which is known to be metabolised by the cytochrome enzyme
             CYP2D6 including flecainide, metoprol, imipramine, amitriptyline, clomipramine.

          -  Family history of sudden unexplained death, or personal or family history of
             predisposing cardiac conditions for arrhythmia/QT prolongation (including congenital
             long QT syndrome, arrhythmia, QTc interval greater than 450 milliseconds with either
             Bazett or Fridericia correction).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjen M Dondorp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol Oxfrod Tropical Medicine Research Unit</affiliation>
  </overall_official>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterolane-piperaquine</keyword>
  <keyword>Dehydroartemisinin-piperaquine</keyword>
  <keyword>therapeutic efficacy</keyword>
  <keyword>Uncomplicated falciparum malaria</keyword>
  <keyword>Artemisinin-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemisinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

